TALPHERA, INC.
About TALPHERA, INC.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2018
- $2.2M
- Net income
- -$14.3M
- Total assets
- $29.7M
- Market cap
- $40.2M
- Operating margin
- -48157.1%
- Net margin
- -51035.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $28.0K
- Operating expenses
- $13.5M
- Operating income
- -$13.5M
- Income tax
- $0
- Net income
- -$14.3M
- EPS (basic)
- $-0.34
Balance sheet
- Total assets
- $29.7M
- Current assets
- $20.9M
- Total liabilities
- $12.7M
- Current liabilities
- $3.8M
- Shareholders’ equity
- $17.0M
Cash flow
- Operating cash flow
- -$11.4M
- Investing cash flow
- -$14.3M
- Financing cash flow
- $22.7M
- Net cash flow
- -$3.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $40.2M
- Shares outstanding
- 47.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 11, 2011
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $14.3M in FY2018.
- Trading 42% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review TALPHERA, INC..
Write a review
News about TALPHERA, INC.
News & sentiment via Polygon.io
